Synthetic method of ezetimibe and its intermediate

Abstract

The invention provides an Ezetimibe synthesis method comprising the following steps: (a) a compound (5) is subjected to asymmetric reduction reaction to obtain a compound (6), and the compound (6) and tert-butyldimethylsilyl chloride react in an organic solution under the action of alkali to obtain a compound (7); (b) the compound (7) and diisopropylethylamine are dissolved in the organic solution, titanium tetrachloride is added in the organic solution to react at 20-50 DEG C, and a compound (3) is added in the organic solution at minus 20 to minus 60 DEG C to react to obtain a compound (8); (c) the compound (8) and N,O-bis(trimethylsilyl) acetamide react in the organic solution at 20-80 DEG C, tetrabutylammonium fluoride trihydrate is added into the organic solution to react at 20-80 DEG C to obtain a compound (9); (d) the compound (9) is subjected to off-protection reaction to obtain Ezetimibe, wherein R is equal to TBS, Ac or COOCH2CCl3. The invention further provides an Ezetimibe intermediate and a preparation method thereof.

Description

technical field [0001] The invention relates to the field of preparation of small molecule chemical drugs, and more particularly relates to a synthesis method of ezetimibe. Background technique [0002] Ezetimibe, also known as Ezetimibe and Ezetimibe, is the first selective cholesterol absorption inhibitor jointly developed by Schering-Plough and Merck. This product is The first selective cholesterol absorption inhibitor drug approved by the US FDA. It was launched in Germany for the first time in November 2002 and was launched in the United States at the same time. [0003] Ezetimibe is the first selective inhibitor of intestinal cholesterol absorption, and its mechanism of action is different from that of other lipid-lowering drugs (such as: statins, bile acid sequestrants, phenoxyacid derivatives and plant sterol esters). Compounds), which can be used alone or in combination with HMG-CoA reductase inhibitors (statins) for the treatment of primary (heterozygous familial...

AI Technical Summary

Problems solved by technology

[0010] The second synthetic route uses the starting material 4-pentenoic acid, which is more expensive and difficult to purchase in the market. The synthetic route is long, the process is complicated, and the reaction conditions are harsh, so it is difficult to realize industrial production.

[0016] Synthetic Method 4, Starting Materials and Catalyst Pd(OAc) 2 The price is more expensive, the process is complex, the reaction conditions are harsh, and it is not easy to scale up production

[0017] In summary, in the above-mentioned synthetic methods, there are problems that the synthetic route is relatively long or the yield and purity are low. Some synthetic route raw materials and precious metal palladium reagents are expensive, and ultra-low temperature reactions are required. The CBS chiral reducing agent used is The amount is large, the solvent is highly toxic

Therefore, the cost of the synthetic method of ezetimibe in the prior art is relatively high, is not suitable for industrialized production

Images